SUBSCRIBE TO OUR FREE NEWSLETTER
Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
5
#000000
#FFFFFF
To donate by check, phone, or other method, see our More Ways to Give page.
Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
"We shouldn't even be here," said one advocate. "This case should have been thrown out way before it got to the Supreme Court."
In its first major abortion decision since reversing Roe v. Wade last year, the U.S. Supreme Court on Friday granted the Biden administration's request to continue allowing widespread access to the medication mifepristone while a legal battle plays out.
"This is very welcome news, but it's frightening to think that Americans came within hours of losing access to a medication that is used in most abortions in this country and has been used for decades by millions of people to safely end a pregnancy or treat a miscarriage," said Jennifer Dalven, director of the ACLU's Reproductive Freedom Project, in response to the order. "Patients shouldn't have to monitor Twitter to see whether they can get the care they need."
"Make no mistake, we aren't out of the woods by any means," Dalven stressed. "This case, which should have been laughed out of court from the very start, will continue on. And as this baseless lawsuit shows, extremists will use every trick in the book to try to ban abortion nationwide."
\u201cWhile we\u2019re glad that access to mifepristone remains for now, judges should never have been deciding the fate of medication abortion.\n\nThis is not over, but we\u2019ll be fighting alongside you, every step of the way.\u201d— Planned Parenthood Action (@Planned Parenthood Action) 1682118141
Nancy Northup, president and CEO of the Center for Reproductive Rights, similarly declared that the decision "is a huge relief, but we're not out of the woods yet."
"For now, providers and patients have the assurance that mifepristone is available" and approved by the Food and Drug Administration (FDA), Northup said. "But we shouldn't even be here. This case should have been thrown out way before it got to the Supreme Court."
President Joe Biden also welcomed that the Supreme Court granted the emergency stay requested by the U.S. Department of Justice (DOJ) in Alliance for Hippocratic Medicine v. FDA, and vowed that his administration will "continue this fight in the courts."
\u201cAs litigation continues, the Biden administration must use every legal means available to give drug manufacturers, distributors, health care providers, and patients the assurances they need to keep this medication available for the millions of women who rely on it.\u201d— Elizabeth Warren (@Elizabeth Warren) 1682118221
The high court's order halts a decision from Texas-based U.S. District Judge Matthew Kacsmaryk, an appointee of former President Donald Trump who earlier this month ruled against the FDA's 2000 approval of mifepristone, in response to a lawsuit brought by right-wing activists ultimately aiming to end abortion care nationwide.
The 5th Circuit Court of Appeals then partially blocked Kacsmaryk's ruling, preserving access to mifepristone—which is often taken in tandem with misoprostol for medication abortions—but reinstating rules that it cannot be dispensed by mail and only can be used up to seven weeks of pregnancy rather than 10.
Justice Samuel Alito temporarily put the 5th Circuit ruling on hold until Wednesday, then extended the deadline by two days. On Friday, he and fellow right-winger Justice Clarence Thomas dissented. While Thomas did not explain his position, Alito wrote in part that allowing the appeals court's decision to take effect while the broader legal fight continues "would simply restore the circumstances that existed (and that the government defended) from 2000 to 2016 under three presidential administrations."
As Alio noted, oral arguments before a three-judge panel from the 5th Circuit are scheduled for mid-May—and, like arguments before Kacsmaryk in March, might feature right-wing attorneys trying to revive a 19th-century obscenity law known as the Comstock Act.
\u201cThe disastrous decision to revive a nineteenth-century obscenity law to limit abortion access is something that, unfortunately, more abortion rights defenders should have seen coming. https://t.co/zANinaaA0d\u201d— The New Republic (@The New Republic) 1682084700
"If it were just up to the science, this case would be thrown out," Dr. Daniel Grossman—an OB-GYN who directs the research program Advancing New Standards in Reproductive Health at the University of California, San Francisco—toldThe Washington Post earlier this month. "We have over two decades of science showing how safe this is."
The Guttmacher Institute tweeted Friday morning: "Remember, we should not be here in the first place. This case is about politics, not the law or facts. Mifepristone is safe, effective, and should be available to everyone seeking medication abortion care."
While some patients and providers already rely on only misoprostol for abortions, using it alone is less effective than pairing the two medications, so "banning mifepristone could mean more money spent, more mental anguish over lingering symptoms of an unwanted pregnancy, and more time spent arranging treatment and figuring out how to step away from work or family responsibilities," Slatenoted. "For people who live in states that restrict abortion, it could mean a second trip across state lines."
"It will also mean more pain and suffering," Slate warned, explaining that "because it takes much more misoprostol to terminate a pregnancy without the assistance of mifepristone—three doses of four tablets, left to dissolve in the mouth, rather than a single dose of four—the physical toll can be harsher," with patients reporting "a higher prevalence of diarrhea, fever, and chills."
\u201cThe Supreme Court just ruled that mifepristone will remain available pending appeal, but the fate of the safe and effective drug used in more than half of all U.S. abortions is still up in the air.\n\nLet's be clear: There's nothing "pro-life" about blocking access to medicine.\u201d— Robert Reich (@Robert Reich) 1682118596
The current legal battle over mifepristone comes as states controlled by anti-choice Republican legislators and governors continue to roll back abortion rights in the wake of the U.S. Supreme Court's right-wing justices reversing Roe last June with their Alito-authored majority decision in Dobbs v. Jackson Women's Health Organization.
In a dozen states—Alabama, Arkansas, Idaho, Kentucky, Louisiana, Mississippi, Missouri, South Dakota, Tennessee, Texas, Oklahoma, and West Virginia—abortion "is completely banned with very limited exceptions," according to the Guttmacher Institute's online tracker.
Guttmacher characterizes policies in another 14 states as "restrictive" or "very restrictive." One of them is Florida, where Republican Gov. Ron DeSantis, a presumed 2024 presidential contender, last week signed a six-week abortion ban that will take effect if the state Supreme Court upholds an earlier 15-week ban.
\u201cIf you are an abortion provider in Pennsylvania, know that your work has never been more important. My Administration has your back.\n\u00a0\nIf you are a patient in a state that's banned the care you need, our doors are open \u2014\u00a0and we will protect you and your provider.\u201d— Governor Josh Shapiro (@Governor Josh Shapiro) 1682117967
Stand Up America managing director for communications Monica Garcia on Friday tied the mifepristone fight to Dobbs, saying that the high court's decision "to overturn Roe v. Wade opened the door for partisan hacks like Judge Kacsmaryk to attack abortion access in the first place."
"If Kascmaryk's ban is allowed to stand, it will have devastating consequences for millions of Americans who rely on mifepristone for abortion care," Garcia said. "We cannot allow the right-wing justices on the court to continue to erode our fundamental freedoms until we no longer recognize the country we live in. Congress has the power to restore balance to this hyperpartisan Supreme Court by expanding the court, and they should use it."
Brett Wilkins contributed to this reporting.
Common Dreams is powered by optimists who believe in the power of informed and engaged citizens to ignite and enact change to make the world a better place. We're hundreds of thousands strong, but every single supporter makes the difference. Your contribution supports this bold media model—free, independent, and dedicated to reporting the facts every day. Stand with us in the fight for economic equality, social justice, human rights, and a more sustainable future. As a people-powered nonprofit news outlet, we cover the issues the corporate media never will. |
In its first major abortion decision since reversing Roe v. Wade last year, the U.S. Supreme Court on Friday granted the Biden administration's request to continue allowing widespread access to the medication mifepristone while a legal battle plays out.
"This is very welcome news, but it's frightening to think that Americans came within hours of losing access to a medication that is used in most abortions in this country and has been used for decades by millions of people to safely end a pregnancy or treat a miscarriage," said Jennifer Dalven, director of the ACLU's Reproductive Freedom Project, in response to the order. "Patients shouldn't have to monitor Twitter to see whether they can get the care they need."
"Make no mistake, we aren't out of the woods by any means," Dalven stressed. "This case, which should have been laughed out of court from the very start, will continue on. And as this baseless lawsuit shows, extremists will use every trick in the book to try to ban abortion nationwide."
\u201cWhile we\u2019re glad that access to mifepristone remains for now, judges should never have been deciding the fate of medication abortion.\n\nThis is not over, but we\u2019ll be fighting alongside you, every step of the way.\u201d— Planned Parenthood Action (@Planned Parenthood Action) 1682118141
Nancy Northup, president and CEO of the Center for Reproductive Rights, similarly declared that the decision "is a huge relief, but we're not out of the woods yet."
"For now, providers and patients have the assurance that mifepristone is available" and approved by the Food and Drug Administration (FDA), Northup said. "But we shouldn't even be here. This case should have been thrown out way before it got to the Supreme Court."
President Joe Biden also welcomed that the Supreme Court granted the emergency stay requested by the U.S. Department of Justice (DOJ) in Alliance for Hippocratic Medicine v. FDA, and vowed that his administration will "continue this fight in the courts."
\u201cAs litigation continues, the Biden administration must use every legal means available to give drug manufacturers, distributors, health care providers, and patients the assurances they need to keep this medication available for the millions of women who rely on it.\u201d— Elizabeth Warren (@Elizabeth Warren) 1682118221
The high court's order halts a decision from Texas-based U.S. District Judge Matthew Kacsmaryk, an appointee of former President Donald Trump who earlier this month ruled against the FDA's 2000 approval of mifepristone, in response to a lawsuit brought by right-wing activists ultimately aiming to end abortion care nationwide.
The 5th Circuit Court of Appeals then partially blocked Kacsmaryk's ruling, preserving access to mifepristone—which is often taken in tandem with misoprostol for medication abortions—but reinstating rules that it cannot be dispensed by mail and only can be used up to seven weeks of pregnancy rather than 10.
Justice Samuel Alito temporarily put the 5th Circuit ruling on hold until Wednesday, then extended the deadline by two days. On Friday, he and fellow right-winger Justice Clarence Thomas dissented. While Thomas did not explain his position, Alito wrote in part that allowing the appeals court's decision to take effect while the broader legal fight continues "would simply restore the circumstances that existed (and that the government defended) from 2000 to 2016 under three presidential administrations."
As Alio noted, oral arguments before a three-judge panel from the 5th Circuit are scheduled for mid-May—and, like arguments before Kacsmaryk in March, might feature right-wing attorneys trying to revive a 19th-century obscenity law known as the Comstock Act.
\u201cThe disastrous decision to revive a nineteenth-century obscenity law to limit abortion access is something that, unfortunately, more abortion rights defenders should have seen coming. https://t.co/zANinaaA0d\u201d— The New Republic (@The New Republic) 1682084700
"If it were just up to the science, this case would be thrown out," Dr. Daniel Grossman—an OB-GYN who directs the research program Advancing New Standards in Reproductive Health at the University of California, San Francisco—toldThe Washington Post earlier this month. "We have over two decades of science showing how safe this is."
The Guttmacher Institute tweeted Friday morning: "Remember, we should not be here in the first place. This case is about politics, not the law or facts. Mifepristone is safe, effective, and should be available to everyone seeking medication abortion care."
While some patients and providers already rely on only misoprostol for abortions, using it alone is less effective than pairing the two medications, so "banning mifepristone could mean more money spent, more mental anguish over lingering symptoms of an unwanted pregnancy, and more time spent arranging treatment and figuring out how to step away from work or family responsibilities," Slatenoted. "For people who live in states that restrict abortion, it could mean a second trip across state lines."
"It will also mean more pain and suffering," Slate warned, explaining that "because it takes much more misoprostol to terminate a pregnancy without the assistance of mifepristone—three doses of four tablets, left to dissolve in the mouth, rather than a single dose of four—the physical toll can be harsher," with patients reporting "a higher prevalence of diarrhea, fever, and chills."
\u201cThe Supreme Court just ruled that mifepristone will remain available pending appeal, but the fate of the safe and effective drug used in more than half of all U.S. abortions is still up in the air.\n\nLet's be clear: There's nothing "pro-life" about blocking access to medicine.\u201d— Robert Reich (@Robert Reich) 1682118596
The current legal battle over mifepristone comes as states controlled by anti-choice Republican legislators and governors continue to roll back abortion rights in the wake of the U.S. Supreme Court's right-wing justices reversing Roe last June with their Alito-authored majority decision in Dobbs v. Jackson Women's Health Organization.
In a dozen states—Alabama, Arkansas, Idaho, Kentucky, Louisiana, Mississippi, Missouri, South Dakota, Tennessee, Texas, Oklahoma, and West Virginia—abortion "is completely banned with very limited exceptions," according to the Guttmacher Institute's online tracker.
Guttmacher characterizes policies in another 14 states as "restrictive" or "very restrictive." One of them is Florida, where Republican Gov. Ron DeSantis, a presumed 2024 presidential contender, last week signed a six-week abortion ban that will take effect if the state Supreme Court upholds an earlier 15-week ban.
\u201cIf you are an abortion provider in Pennsylvania, know that your work has never been more important. My Administration has your back.\n\u00a0\nIf you are a patient in a state that's banned the care you need, our doors are open \u2014\u00a0and we will protect you and your provider.\u201d— Governor Josh Shapiro (@Governor Josh Shapiro) 1682117967
Stand Up America managing director for communications Monica Garcia on Friday tied the mifepristone fight to Dobbs, saying that the high court's decision "to overturn Roe v. Wade opened the door for partisan hacks like Judge Kacsmaryk to attack abortion access in the first place."
"If Kascmaryk's ban is allowed to stand, it will have devastating consequences for millions of Americans who rely on mifepristone for abortion care," Garcia said. "We cannot allow the right-wing justices on the court to continue to erode our fundamental freedoms until we no longer recognize the country we live in. Congress has the power to restore balance to this hyperpartisan Supreme Court by expanding the court, and they should use it."
Brett Wilkins contributed to this reporting.
In its first major abortion decision since reversing Roe v. Wade last year, the U.S. Supreme Court on Friday granted the Biden administration's request to continue allowing widespread access to the medication mifepristone while a legal battle plays out.
"This is very welcome news, but it's frightening to think that Americans came within hours of losing access to a medication that is used in most abortions in this country and has been used for decades by millions of people to safely end a pregnancy or treat a miscarriage," said Jennifer Dalven, director of the ACLU's Reproductive Freedom Project, in response to the order. "Patients shouldn't have to monitor Twitter to see whether they can get the care they need."
"Make no mistake, we aren't out of the woods by any means," Dalven stressed. "This case, which should have been laughed out of court from the very start, will continue on. And as this baseless lawsuit shows, extremists will use every trick in the book to try to ban abortion nationwide."
\u201cWhile we\u2019re glad that access to mifepristone remains for now, judges should never have been deciding the fate of medication abortion.\n\nThis is not over, but we\u2019ll be fighting alongside you, every step of the way.\u201d— Planned Parenthood Action (@Planned Parenthood Action) 1682118141
Nancy Northup, president and CEO of the Center for Reproductive Rights, similarly declared that the decision "is a huge relief, but we're not out of the woods yet."
"For now, providers and patients have the assurance that mifepristone is available" and approved by the Food and Drug Administration (FDA), Northup said. "But we shouldn't even be here. This case should have been thrown out way before it got to the Supreme Court."
President Joe Biden also welcomed that the Supreme Court granted the emergency stay requested by the U.S. Department of Justice (DOJ) in Alliance for Hippocratic Medicine v. FDA, and vowed that his administration will "continue this fight in the courts."
\u201cAs litigation continues, the Biden administration must use every legal means available to give drug manufacturers, distributors, health care providers, and patients the assurances they need to keep this medication available for the millions of women who rely on it.\u201d— Elizabeth Warren (@Elizabeth Warren) 1682118221
The high court's order halts a decision from Texas-based U.S. District Judge Matthew Kacsmaryk, an appointee of former President Donald Trump who earlier this month ruled against the FDA's 2000 approval of mifepristone, in response to a lawsuit brought by right-wing activists ultimately aiming to end abortion care nationwide.
The 5th Circuit Court of Appeals then partially blocked Kacsmaryk's ruling, preserving access to mifepristone—which is often taken in tandem with misoprostol for medication abortions—but reinstating rules that it cannot be dispensed by mail and only can be used up to seven weeks of pregnancy rather than 10.
Justice Samuel Alito temporarily put the 5th Circuit ruling on hold until Wednesday, then extended the deadline by two days. On Friday, he and fellow right-winger Justice Clarence Thomas dissented. While Thomas did not explain his position, Alito wrote in part that allowing the appeals court's decision to take effect while the broader legal fight continues "would simply restore the circumstances that existed (and that the government defended) from 2000 to 2016 under three presidential administrations."
As Alio noted, oral arguments before a three-judge panel from the 5th Circuit are scheduled for mid-May—and, like arguments before Kacsmaryk in March, might feature right-wing attorneys trying to revive a 19th-century obscenity law known as the Comstock Act.
\u201cThe disastrous decision to revive a nineteenth-century obscenity law to limit abortion access is something that, unfortunately, more abortion rights defenders should have seen coming. https://t.co/zANinaaA0d\u201d— The New Republic (@The New Republic) 1682084700
"If it were just up to the science, this case would be thrown out," Dr. Daniel Grossman—an OB-GYN who directs the research program Advancing New Standards in Reproductive Health at the University of California, San Francisco—toldThe Washington Post earlier this month. "We have over two decades of science showing how safe this is."
The Guttmacher Institute tweeted Friday morning: "Remember, we should not be here in the first place. This case is about politics, not the law or facts. Mifepristone is safe, effective, and should be available to everyone seeking medication abortion care."
While some patients and providers already rely on only misoprostol for abortions, using it alone is less effective than pairing the two medications, so "banning mifepristone could mean more money spent, more mental anguish over lingering symptoms of an unwanted pregnancy, and more time spent arranging treatment and figuring out how to step away from work or family responsibilities," Slatenoted. "For people who live in states that restrict abortion, it could mean a second trip across state lines."
"It will also mean more pain and suffering," Slate warned, explaining that "because it takes much more misoprostol to terminate a pregnancy without the assistance of mifepristone—three doses of four tablets, left to dissolve in the mouth, rather than a single dose of four—the physical toll can be harsher," with patients reporting "a higher prevalence of diarrhea, fever, and chills."
\u201cThe Supreme Court just ruled that mifepristone will remain available pending appeal, but the fate of the safe and effective drug used in more than half of all U.S. abortions is still up in the air.\n\nLet's be clear: There's nothing "pro-life" about blocking access to medicine.\u201d— Robert Reich (@Robert Reich) 1682118596
The current legal battle over mifepristone comes as states controlled by anti-choice Republican legislators and governors continue to roll back abortion rights in the wake of the U.S. Supreme Court's right-wing justices reversing Roe last June with their Alito-authored majority decision in Dobbs v. Jackson Women's Health Organization.
In a dozen states—Alabama, Arkansas, Idaho, Kentucky, Louisiana, Mississippi, Missouri, South Dakota, Tennessee, Texas, Oklahoma, and West Virginia—abortion "is completely banned with very limited exceptions," according to the Guttmacher Institute's online tracker.
Guttmacher characterizes policies in another 14 states as "restrictive" or "very restrictive." One of them is Florida, where Republican Gov. Ron DeSantis, a presumed 2024 presidential contender, last week signed a six-week abortion ban that will take effect if the state Supreme Court upholds an earlier 15-week ban.
\u201cIf you are an abortion provider in Pennsylvania, know that your work has never been more important. My Administration has your back.\n\u00a0\nIf you are a patient in a state that's banned the care you need, our doors are open \u2014\u00a0and we will protect you and your provider.\u201d— Governor Josh Shapiro (@Governor Josh Shapiro) 1682117967
Stand Up America managing director for communications Monica Garcia on Friday tied the mifepristone fight to Dobbs, saying that the high court's decision "to overturn Roe v. Wade opened the door for partisan hacks like Judge Kacsmaryk to attack abortion access in the first place."
"If Kascmaryk's ban is allowed to stand, it will have devastating consequences for millions of Americans who rely on mifepristone for abortion care," Garcia said. "We cannot allow the right-wing justices on the court to continue to erode our fundamental freedoms until we no longer recognize the country we live in. Congress has the power to restore balance to this hyperpartisan Supreme Court by expanding the court, and they should use it."
Brett Wilkins contributed to this reporting.